Overall verdict
Neutral
6.3/10
1-year performance
-18.48%
Score breakdown
Down 18.5% over 1 year, 7% of the 52-week range.
Strongest: Profitability 9.2/10. Weakest: Valuation 2.6/10.
14 analysts, target +0.3% vs the price.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits.
It also provides commercial reference laboratory diagnostic and consulting services to veterinarians ; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting ; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water ; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments ;
UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests ; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry ; human medical diagnostic products and services ; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station.
It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Sector
Health Care
Industry
Health Care Equipment and Supplies
Primary listing
Nasdaq
United States
CEO
Michael Erickson
Founded
1983
Employees
11 000
Revenue / employee
391 246 USD
Next earnings
November 6, 2026 (estimated)
Institutional holders
- BlackRock, Inc.10.30%
- VANGUARD CAPITAL MANAGEMENT LLC6.49%
- VANGUARD PORTFOLIO MANAGEMENT LLC4.91%
- STATE STREET CORP4.72%
- Invesco Ltd.4.55%
- GEODE CAPITAL MANAGEMENT, LLC3.23%
- BAMCO INC /NY/2.49%
- MORGAN STANLEY1.71%
- Bank of New York Mellon Corp1.50%
- Other institutions53.56%
- Rest of the register6.53%
1299 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
769.98 USD
52-week low
500.61 USD
1-year performance
-18.48%
Declining
Year-to-date performance
-22.84%
Declining
Drawdown
-32.68%
Major drawdown
Position in the 52-week range
7% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned more, but shaking 2.3 times harder: for the risk taken, the ETF paid better.
10,000 € placed at the end of September 2009 are worth today
| IDEXX Laboratories | 279 930 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 2.3 times as much as the world ETF.
- Worst fall:-48 % between August 2021 and June 2022. 10,000 € placed at the top fell to 5 214 €. The world ETF, at worst: -34 %. Back to its high in 41 months.
IDEXX Laboratories earned 4 times as much as the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- IDEXX Laboratories: 279 930 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 315.51 USD - 327.86 USD (2 methods agree)
The price implies growth of 11.50% per year; the company grows at 14.28%.
Gross margin 62.5%, net margin 25.0%, ROIC 56.6%, ROE 74.2%.
Net margin
25.03%
Exceptional
Sector 8.18%|S&P 12.97%
Gross margin
62.53%
Fair
Return on equity (ROE)
74.21%
Exceptional
Sector 6.97%|S&P 16.52%
Return on invested capital (ROIC)
56.57%
Exceptional
Free cash flow margin (FCF)
27.47%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.10x
High
Margin stability
4.0 pts
Steady
Revenue to net income
Growth
7.3/10Revenue up 9.7% over 1 year, 9.7% a year over 5, EPS 14.3% a year over 5.
Revenue (trailing 12 months)
4.6Md USD
Revenue growth (1y)
9.66%
Solid
Revenue growth (3y)
27.81%
Solid
EPS growth (1y)
17.55%
Hyper-growth
EPS CAGR (5y)
14.28%
Strong
EPS revisions (3 months)
1.13%
Revised up
Valuation
2.6/10P/E 36.4x, forward P/E 35.1x, EV/EBITDA 25.7x, PEG 2.55. The multiple sits in the 5th percentile of its own 5-year history.
P/E (TTM)
36.4x
Expensive
Sector 28.9x|S&P 23.0x
Forward P/E
35.1x
Expensive
EV / EBITDA
25.7x
Expensive
Sector 15.7x|S&P 14.5x
PEG
2.55
Very expensive
Sector 1.76|S&P 0.86
Fair value (reverse DCF)
321.68 USD
Deeply overvalued
P/E vs its own 5-year history
among the 5% lowest valuations
Far cheaper than usual
Market cap
41.1Md USD
Financial strength
8.4/10Cash covers 18.0% of the debt, net debt/EBITDA 0.5x.
Net debt / EBITDA
0.5x
Solid
Gearing (net debt / equity)
55.76%
Solid
Cash
197M USD
Cash / market cap
0.48%
Stretched
Cash / total debt
17.97%
Tight
Interest coverage
38.6x
Very solid
Net debt
899M USD
Equity
1.6Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 513.47 USD
- MM20523.82
- MM50547.88
- MM200593.35
- RSI 1440.6
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-3.27%
200-day average slope, 3 months
-5.91%
50-day average slope, 1 month
-2.13%
Price structure
Lower lows
Bullish RSI divergence
Yes
20-day volatility
1.31 % per day
Volatility change
-29.87%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 14.77 (11) | 14.83 (13) | 4 724 (13) | 1 688 (10) | 1 179 (10) |
| 2027 | 16.70 (11) | 16.74 (13) | 5 141 (13) | 1 857 (10) | 1 315 (10) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 15, 2026.
Same sub-industry: 190 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BSX | 7.0 | 7.2 | 64.7Md USD | 18.1x | 17.5 % | 7.5 % | 10.5 % | 1.8x | 5.6 % | -54.3 % | ||
| 2 | MDT | 6.9 | 6.9 | 114Md USD | 22.0x | 13.9 % | 13.7 % | 7.0 % | 2.0x | 5.4 % | -6.7 % | ||
| 3 | SYK | 6.9 | 7.5 | 105Md USD | 28.3x | 14.4 % | 9.4 % | 10.0 % | 1.7x | 4.5 % | -27.6 % | ||
| 4 | ABT | 6.6 | 6.3 | 179Md USD | 33.5x | 11.6 % | 13.0 % | 7.5 % | 0.5x | 4.4 % | -25.3 % | ||
| 5 | ISRG | 6.5 | 6.8 | 141Md USD | 45.6x | 28.4 % | 18.5 % | 17.4 % | -1.6x | 2.3 % | -11.4 % | ||
| 6 | IDXX | 6.3 | 6.2 | 41.1Md USD | 36.4x | 25.0 % | 9.7 % | 56.6 % | 0.5x | 3.0 % | -18.5 % | ||
| 7 | SHL | 6.3 | 6.5 | 47.2Md USD | 18.9x | 9.6 % | 1.8 % | 7.4 % | 2.7x | 5.4 % | -20.5 % | ||
| 8 | EW | 6.1 | 5.4 | 50.0Md USD | 51.5x | 15.0 % | 13.6 % | 8.7 % | -2.0x | 2.9 % | 15.4 % | ||
| 9 | BDX | 5.7 | 5.1 | 49.7Md USD | 55.1x | 6.2 % | 5.4 % | 3.2 % | 3.4x | 5.1 % | 22.7 % |
